Leerink Partnrs Has Pessimistic Outlook of LXEO Q2 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Lexeo Therapeutics in a research note issued on Monday, May 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.82) per share for the quarter, down from their prior forecast of ($0.80). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($3.29) EPS, FY2026 earnings at ($2.69) EPS and FY2027 earnings at ($2.65) EPS.

LXEO has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, April 8th. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Royal Bank of Canada cut their price objective on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 25th. Finally, Chardan Capital cut their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $21.80.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $2.69 on Thursday. The company has a 50-day moving average of $3.06 and a 200-day moving average of $5.06. The firm has a market cap of $89.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.27. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a twelve month low of $1.45 and a twelve month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.19).

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC raised its stake in Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock valued at $28,508,000 after purchasing an additional 576,059 shares during the last quarter. Affinity Asset Advisors LLC acquired a new stake in Lexeo Therapeutics during the first quarter worth about $5,139,000. Vestal Point Capital LP increased its stake in Lexeo Therapeutics by 41.2% during the fourth quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock valued at $7,896,000 after acquiring an additional 350,000 shares during the period. Woodline Partners LP raised its holdings in Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock valued at $5,650,000 after acquiring an additional 6,730 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock worth $4,937,000 after purchasing an additional 379,828 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.